The ATIC study73 of patients with CKD stages 2–4 reported that treatment reduced urinary albumin excretion and provided medians and ranges of the AER (77, 3–2509 mg/24 hours for the intervention group, and 107, 5–3545 mg/24 hours for the comparator group). The gene discussed is ALB; the disease is chronic kidney disease.